|
AU2005298932B2
(en)
*
|
2004-10-20 |
2012-03-22 |
Merck Serono Sa |
3-arylamino pyridine derivatives
|
|
DE602006021205D1
(de)
*
|
2005-10-07 |
2011-05-19 |
Exelixis Inc |
Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
AU2007284562B2
(en)
*
|
2006-08-16 |
2013-05-02 |
Exelixis, Inc. |
Using PI3K and MEK modulators in treatments of cancer
|
|
US7943659B2
(en)
|
2006-10-31 |
2011-05-17 |
Takeda Pharmaceutical Company Limited |
MAPK/ERK kinase inhibitors
|
|
JP5311673B2
(ja)
*
|
2006-12-14 |
2013-10-09 |
エグゼリクシス， インコーポレイテッド |
Ｍｅｋ阻害剤の使用方法
|
|
WO2008124085A2
(en)
*
|
2007-04-03 |
2008-10-16 |
Exelixis, Inc. |
Methods of using combinations of mek and jak-2 inhibitors
|
|
KR20100009582A
(ko)
*
|
2007-05-10 |
2010-01-27 |
화이자 리미티드 |
아제티딘 유도체 및 프로스타글란딘 ｅ2 길항제로서 그의 용도
|
|
PL2474557T3
(pl)
|
2007-07-16 |
2015-02-27 |
Genentech Inc |
Przeciwciała anty- CD79b i immunokoniugaty i sposoby stosowania
|
|
WO2009012256A1
(en)
|
2007-07-16 |
2009-01-22 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
|
EP2240494B1
(en)
|
2008-01-21 |
2016-03-30 |
UCB Biopharma SPRL |
Thieno-pyridine derivatives as mek inhibitors
|
|
NZ587132A
(en)
|
2008-01-31 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
EP2644204B1
(en)
|
2008-03-18 |
2017-04-19 |
Genentech, Inc. |
Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
WO2010003025A1
(en)
|
2008-07-01 |
2010-01-07 |
Genentech, Inc. |
Bicyclic heterocycles as mek kinase inhibitors
|
|
MX2010014565A
(es)
|
2008-07-01 |
2011-03-04 |
Genentech Inc |
Isoindolona y metodos de uso.
|
|
WO2010068738A1
(en)
|
2008-12-10 |
2010-06-17 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
|
US8536161B2
(en)
|
2009-03-12 |
2013-09-17 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
|
|
CN102459272B
(zh)
|
2009-05-27 |
2014-08-06 |
健泰科生物技术公司 |
对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法
|
|
AU2010299820A1
(en)
|
2009-09-28 |
2012-04-19 |
F. Hoffmann-La Roche Ag |
Benzoxepin PI3K inhibitor compounds and methods of use
|
|
PL2483278T3
(pl)
|
2009-09-28 |
2014-05-30 |
Hoffmann La Roche |
Związki benzoksazepinowe stanowiące inhibitor pi3k i ich zastosowanie w leczeniu nowotworu
|
|
JP2013507415A
(ja)
*
|
2009-10-12 |
2013-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｉ３ｋ阻害剤とｍｅｋ阻害剤の併用
|
|
MY156209A
(en)
*
|
2009-11-04 |
2016-01-29 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful mek inhibitors
|
|
WO2011069074A2
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
|
|
CA2787714C
(en)
|
2010-01-22 |
2019-04-09 |
Joaquin Pastor Fernandez |
Inhibitors of pi3 kinase
|
|
EP2539337A1
(en)
|
2010-02-22 |
2013-01-02 |
F. Hoffmann-La Roche AG |
Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
|
|
WO2011106298A1
(en)
|
2010-02-25 |
2011-09-01 |
Dana-Farber Cancer Institute, Inc. |
Braf mutations conferring resistance to braf inhibitors
|
|
CN103038364A
(zh)
|
2010-03-09 |
2013-04-10 |
达纳－法伯癌症研究所公司 |
诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
|
|
WO2011121317A1
(en)
|
2010-04-01 |
2011-10-06 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
|
|
SG184475A1
(en)
|
2010-04-07 |
2012-11-29 |
Hoffmann La Roche |
Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
|
|
TWI540136B
(zh)
|
2010-04-15 |
2016-07-01 |
梅迪繆思有限公司 |
吡咯并苯并二氮呯及其共軛物
|
|
WO2011140488A1
(en)
|
2010-05-07 |
2011-11-10 |
Gilead Connecticut, Inc. |
Pyridone and aza-pyridone compounds and methods of use
|
|
EP2593455B1
(en)
|
2010-07-14 |
2015-03-18 |
F.Hoffmann-La Roche Ag |
Purine compounds selective for i3 p110 delta, and methods of use
|
|
CA2806670A1
(en)
|
2010-07-26 |
2012-02-09 |
Biomatrica, Inc. |
Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
|
|
EP2598661B1
(en)
|
2010-07-26 |
2017-09-27 |
Biomatrica, INC. |
Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
|
|
CN103201277B
(zh)
|
2010-09-01 |
2015-11-25 |
吉利德康涅狄格有限公司 |
哒嗪酮、其制备方法及使用方法
|
|
EP2611790B1
(en)
|
2010-09-01 |
2015-11-04 |
Gilead Connecticut, Inc. |
Pyridinones/pyrazinones, method of making, and method of use thereof
|
|
WO2012052745A1
(en)
|
2010-10-21 |
2012-04-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Combinations of pi3k inhibitors with a second anti -tumor agent
|
|
WO2012068096A2
(en)
|
2010-11-15 |
2012-05-24 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
|
|
SG10201510347QA
(en)
|
2010-12-16 |
2016-01-28 |
Hoffmann La Roche |
Tricyclic pi3k inhibitor compounds and methods of use
|
|
EP2673269A1
(en)
|
2011-02-09 |
2013-12-18 |
F.Hoffmann-La Roche Ag |
Heterocyclic compounds as pi3 kinase inhibitors
|
|
CA2825966A1
(en)
|
2011-03-21 |
2012-09-27 |
F. Hoffmann-La Roche Ag |
Benzoxazepin compounds selective for pi3k p110 delta and methods of use
|
|
CN102718750B
(zh)
*
|
2011-03-31 |
2015-03-11 |
中国人民解放军军事医学科学院毒物药物研究所 |
含吖啶环的氨基吡啶类衍生物及其用途
|
|
SG194052A1
(en)
|
2011-04-01 |
2013-11-29 |
Genentech Inc |
Combinations of akt inhibitor compounds and erlotinib, and methods of use
|
|
JP6147246B2
(ja)
*
|
2011-04-01 |
2017-06-14 |
ジェネンテック， インコーポレイテッド |
Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
|
|
RU2598840C2
(ru)
|
2011-05-19 |
2016-09-27 |
Фундасион Сентро Насиональ Де Инвестигасионес Онколохикас Карлос Iii |
Новые соединения
|
|
EP2524918A1
(en)
|
2011-05-19 |
2012-11-21 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Imidazopyrazines derivates as kinase inhibitors
|
|
JP2014515390A
(ja)
|
2011-06-03 |
2014-06-30 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｉ３ｋ阻害剤化合物を用いた中皮腫の治療法
|
|
TR201820873T4
(tr)
*
|
2011-08-01 |
2019-01-21 |
Hoffmann La Roche |
Pd-1 ekseni bağlayıcı antagonistler ve mek inhibitörlerinin kullanıldığı kanser tedavisine yönelik yöntemler.
|
|
EP2742046A1
(en)
|
2011-08-12 |
2014-06-18 |
F.Hoffmann-La Roche Ag |
PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
|
|
US8614206B2
(en)
|
2011-09-27 |
2013-12-24 |
F. Hoffmann-La Roche Ag |
Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
|
|
HRP20151374T1
(hr)
|
2011-10-14 |
2016-01-15 |
Medimmune Limited |
Pirolobenzodiazepini i njihovi konjugati
|
|
SG11201401815XA
(en)
*
|
2011-10-28 |
2014-05-29 |
Genentech Inc |
Therapeutic combinations and methods of treating melanoma
|
|
UA111756C2
(uk)
|
2011-11-03 |
2016-06-10 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
|
|
JP5808869B2
(ja)
|
2011-11-03 |
2015-11-10 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二環式ピペラジン化合物
|
|
JP5976828B2
(ja)
|
2011-11-03 |
2016-08-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｂｔｋ活性阻害剤としてのアルキル化ピペラジン化合物
|
|
AR088643A1
(es)
|
2011-11-03 |
2014-06-25 |
Genentech Inc |
Compuestos de 8-fluoroftalazin-1(2h)-ona
|
|
EP2592103A1
(en)
|
2011-11-08 |
2013-05-15 |
Adriacell S.p.A. |
Polymer aldehyde derivatives
|
|
HK1202877A1
(en)
|
2011-11-23 |
2015-10-09 |
伊格尼卡生物治疗公司 |
Anti-cd98 antibodies and methods of use thereof
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
CN103204825B
(zh)
|
2012-01-17 |
2015-03-04 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
|
|
WO2013113102A1
(en)
|
2012-02-01 |
2013-08-08 |
The Governors Of The University Of Alberta |
USE OF PDGFR-α AS DIAGNOSTIC MARKER FOR PAPILLARY THYROID CANCER
|
|
US20150141470A1
(en)
|
2012-05-08 |
2015-05-21 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
NZ702244A
(en)
|
2012-06-08 |
2017-06-30 |
Hoffmann La Roche |
Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
|
|
EP2867232B1
(en)
|
2012-06-27 |
2018-08-08 |
F.Hoffmann-La Roche Ag |
5-azaindazole compounds and methods of use
|
|
EP2879708A4
(en)
|
2012-08-02 |
2016-03-16 |
Genentech Inc |
ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES
|
|
CN104797270A
(zh)
|
2012-08-02 |
2015-07-22 |
基因泰克公司 |
抗etbr抗体和免疫偶联物
|
|
ES2765573T3
(es)
*
|
2012-08-13 |
2020-06-09 |
Univ Rockefeller |
Tratamiento y diagnóstico de melanoma
|
|
SI2884979T1
(sl)
|
2012-08-17 |
2019-10-30 |
Hoffmann La Roche |
Kombinirana zdravljenja melanoma, ki vključujejo dajanje kobimetiniba in vemurafeniba
|
|
WO2014033196A1
(en)
|
2012-08-30 |
2014-03-06 |
F. Hoffmann-La Roche Ag |
Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use
|
|
KR102281288B1
(ko)
|
2012-09-26 |
2021-07-26 |
에프. 호프만-라 로슈 아게 |
환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법
|
|
EP2906598A1
(en)
|
2012-10-09 |
2015-08-19 |
Igenica Biotherapeutics, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
|
US10736903B2
(en)
|
2012-10-12 |
2020-08-11 |
Medimmune Limited |
Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
|
|
SI2906251T1
(en)
|
2012-10-12 |
2018-01-31 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
|
|
CA2941485C
(en)
|
2012-10-12 |
2018-06-12 |
Philip Wilson Howard |
Pyrrolobenzodiazepines and conjugates thereof
|
|
DK2906296T3
(en)
|
2012-10-12 |
2018-05-22 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
PL2906253T3
(pl)
|
2012-10-12 |
2019-02-28 |
Adc Therapeutics Sa |
Koniugaty pirolobenzodiazepina-przeciwciało anty-psma
|
|
SMT201900017T1
(it)
|
2012-10-12 |
2019-02-28 |
Medimmune Ltd |
Coniugati pirrolobenzodiazepina-anticorpo
|
|
CN104837826B
(zh)
*
|
2012-10-12 |
2018-07-27 |
埃克塞里艾克西斯公司 |
制备用于治疗癌症的化合物的新型方法
|
|
CN110256469B
(zh)
|
2012-10-12 |
2022-05-17 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
|
US10695433B2
(en)
|
2012-10-12 |
2020-06-30 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
WO2014074785A1
(en)
|
2012-11-08 |
2014-05-15 |
Ludwig Institute For Cancer Research Ltd. |
Methods of predicting outcome and treating breast cancer
|
|
CA2889381C
(en)
*
|
2012-11-15 |
2023-01-03 |
Duquesne University Of The Holy Ghost |
Carboxylic acid ester prodrug inhibitors of mek
|
|
TW201441193A
(zh)
*
|
2012-12-06 |
2014-11-01 |
Kyowa Hakko Kirin Co Ltd |
吡啶酮化合物
|
|
EP3249054A1
(en)
|
2012-12-20 |
2017-11-29 |
Biomatrica, INC. |
Formulations and methods for stabilizing pcr reagents
|
|
US9567340B2
(en)
|
2012-12-21 |
2017-02-14 |
Medimmune Limited |
Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
|
|
BR112015014669B1
(pt)
|
2012-12-21 |
2023-09-26 |
Medimmune Limited |
Compostos pirrolobenzodiazepinas, conjugados compreendendo os mesmos e uso destes para tratar uma doença proliferativa
|
|
US9968687B2
(en)
|
2013-02-22 |
2018-05-15 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibody drug conjugates
|
|
HK1211235A1
(en)
|
2013-02-22 |
2016-05-20 |
霍夫曼-拉罗奇有限公司 |
Methods of treating cancer and preventing drug resistance
|
|
US10139415B2
(en)
|
2013-02-27 |
2018-11-27 |
Daiichi Sankyo Company, Limited |
Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway
|
|
AU2014244245C1
(en)
|
2013-03-13 |
2018-04-19 |
Genentech, Inc. |
Pyrrolobenzodiazepines and conjugates thereof
|
|
NZ710746A
(en)
|
2013-03-13 |
2018-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
AU2014230735B2
(en)
|
2013-03-13 |
2018-03-15 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
|
PL2968346T3
(pl)
|
2013-03-15 |
2024-11-04 |
Cancer Research Technologies Llc |
Sposoby i kompozycje do modulacji cyklu gamma-glutamylowego
|
|
WO2014153495A2
(en)
|
2013-03-22 |
2014-09-25 |
University Of Hawaii |
Novel stat3 inhibitors
|
|
ES2891755T3
(es)
|
2013-06-06 |
2022-01-31 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
|
EP3007556B1
(en)
|
2013-06-13 |
2020-05-20 |
Biomatrica, INC. |
Cell stabilization
|
|
CN110698481B
(zh)
|
2013-07-03 |
2023-02-28 |
豪夫迈·罗氏有限公司 |
杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物
|
|
PE20160674A1
(es)
|
2013-08-28 |
2016-07-21 |
Stemcentrx Inc |
Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
|
|
US9532987B2
(en)
*
|
2013-09-05 |
2017-01-03 |
Genentech, Inc. |
Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
|
|
CA2924286C
(en)
|
2013-09-17 |
2022-06-21 |
Obi Pharma, Inc. |
Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
|
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP3054983B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US9956299B2
(en)
|
2013-10-11 |
2018-05-01 |
Medimmune Limited |
Pyrrolobenzodiazepine—antibody conjugates
|
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP3077384B1
(en)
|
2013-12-05 |
2017-09-06 |
F. Hoffmann-La Roche AG |
Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
|
|
WO2015108203A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社オーダーメードメディカルリサーチ |
抗ｓｌｃ６ａ６抗体を用いたがん治療用医薬組成物
|
|
CN104788365B
(zh)
*
|
2014-01-16 |
2018-08-10 |
上海艾力斯医药科技有限公司 |
异烟酰胺衍生物、其制备方法及应用
|
|
RU2016137761A
(ru)
|
2014-03-18 |
2018-04-18 |
Ф. Хоффманн-Ля Рош Аг |
Оксепан-2-ил-пиразол-4-ил-гетероциклил-карбоксамиды и способы их применения
|
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
|
WO2015166355A2
(en)
|
2014-04-18 |
2015-11-05 |
The Governors Of The University Of Alberta |
Targeted therapy to restore radioactive iodine transport in thyroid cancer
|
|
KR20160141857A
(ko)
|
2014-04-25 |
2016-12-09 |
제넨테크, 인크. |
트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
|
|
WO2015172073A1
(en)
|
2014-05-08 |
2015-11-12 |
Cornell University |
Bio-adhesive gels and methods of use
|
|
WO2015182734A1
(ja)
*
|
2014-05-30 |
2015-12-03 |
協和発酵キリン株式会社 |
含窒素複素環化合物
|
|
JP6661554B2
(ja)
|
2014-06-10 |
2020-03-11 |
バイオマトリカ，インク． |
周囲温度における血小板の安定化
|
|
SG11201700074YA
(en)
|
2014-07-15 |
2017-02-27 |
Genentech Inc |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
AR101844A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos y conjugados modificados genéticamente con cisteína
|
|
CN107001479B
(zh)
|
2014-09-12 |
2021-09-28 |
基因泰克公司 |
抗her2抗体和免疫缀合物
|
|
KR20170055521A
(ko)
|
2014-09-17 |
2017-05-19 |
제넨테크, 인크. |
항-her2 항체를 포함하는 면역콘주게이트
|
|
CR20170099A
(es)
|
2014-09-17 |
2017-07-19 |
Genentech Inc |
Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
|
|
CN106922146B
(zh)
|
2014-10-02 |
2020-05-26 |
豪夫迈·罗氏有限公司 |
用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
|
|
WO2016061253A1
(en)
|
2014-10-14 |
2016-04-21 |
Exelixis, Inc. |
Drug combination to treat melanoma
|
|
MX379396B
(es)
|
2014-11-25 |
2025-03-11 |
Adc Therapeutics Sa |
Conjugados de pirrolobenzodiazepina y anticuerpo.
|
|
CN114230664B
(zh)
|
2014-12-11 |
2025-01-03 |
皮埃尔法布雷医药公司 |
抗c10orf54抗体及其用途
|
|
WO2016095089A1
(en)
|
2014-12-15 |
2016-06-23 |
Merck Sharp & Dohme Corp. |
Erk inhibitors
|
|
WO2016095088A1
(en)
|
2014-12-15 |
2016-06-23 |
Merck Sharp & Dohme Corp. |
Erk inhibitors
|
|
EA032311B1
(ru)
|
2014-12-18 |
2019-05-31 |
Ф. Хоффманн-Ля Рош Аг |
Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение
|
|
EP3280806A4
(en)
|
2015-04-10 |
2018-12-05 |
Thomas Jefferson University |
Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
JP6822980B2
(ja)
|
2015-05-30 |
2021-01-27 |
ジェネンテック， インコーポレイテッド |
Ｈｅｒ２陽性転移性乳癌の治療方法
|
|
HK1255483A1
(zh)
|
2015-06-15 |
2019-08-16 |
基因泰克公司 |
抗体和免疫结合物
|
|
JP6914202B2
(ja)
|
2015-06-30 |
2021-08-04 |
ジェネンテック， インコーポレイテッド |
薬物を含有する即放性錠剤及び錠剤の形成プロセス
|
|
AR105483A1
(es)
|
2015-06-30 |
2017-10-11 |
Exelixis Inc |
Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
|
|
SI3317284T1
(sl)
|
2015-07-02 |
2020-02-28 |
F. Hoffmann-La Roche Ag |
Spojine benzoksazepin oksazolidinona in načini uporabe
|
|
CN107995911B
(zh)
|
2015-07-02 |
2020-08-04 |
豪夫迈·罗氏有限公司 |
苯并氧氮杂*噁唑烷酮化合物及其使用方法
|
|
WO2017033113A1
(en)
|
2015-08-21 |
2017-03-02 |
Acerta Pharma B.V. |
Therapeutic combinations of a mek inhibitor and a btk inhibitor
|
|
HK1256912A1
(zh)
|
2015-09-04 |
2019-10-04 |
台湾浩鼎生技股份有限公司 |
聚糖阵列以及使用方法
|
|
EP3370775B1
(en)
|
2015-11-03 |
2023-04-19 |
Genentech, Inc. |
Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
EP3377107B1
(en)
|
2015-11-19 |
2020-08-12 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors
|
|
CN113588501B
(zh)
|
2015-12-08 |
2024-12-17 |
生物马特里卡公司 |
降低红细胞沉降速率
|
|
CN105330643B
(zh)
*
|
2015-12-09 |
2017-12-05 |
苏州明锐医药科技有限公司 |
卡比替尼的制备方法
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
CA3236518A1
(en)
|
2016-02-29 |
2017-09-08 |
F. Hoffmann-La Roche Ag |
Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
|
|
WO2017150725A1
(ja)
|
2016-03-04 |
2017-09-08 |
大鵬薬品工業株式会社 |
悪性腫瘍治療用製剤及び組成物
|
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
JP2019513144A
(ja)
|
2016-03-29 |
2019-05-23 |
オービーアイ ファーマ，インコーポレイテッド |
抗体、医薬組成物及び方法
|
|
AU2017249229A1
(en)
|
2016-04-15 |
2018-10-04 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
KR20230110820A
(ko)
|
2016-04-22 |
2023-07-25 |
오비아이 파머 인코퍼레이티드 |
글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
CN106045969B
(zh)
*
|
2016-05-27 |
2019-04-12 |
湖南欧亚药业有限公司 |
一种卡比替尼的合成方法
|
|
WO2017216279A1
(en)
|
2016-06-16 |
2017-12-21 |
F. Hoffmann-La Roche Ag |
Heteroaryl estrogen receptor modulators and uses thereof
|
|
CN109843882A
(zh)
|
2016-06-16 |
2019-06-04 |
豪夫迈·罗氏有限公司 |
四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
|
|
KR20190067765A
(ko)
|
2016-07-27 |
2019-06-17 |
오비아이 파머 인코퍼레이티드 |
면역원성/치료 글리칸 조성물 및 그의 용도
|
|
CN106220607B
(zh)
*
|
2016-07-27 |
2018-09-18 |
成都百事兴科技实业有限公司 |
一种s-3-(哌啶-2-基)-氮杂环丁烷-3-醇的合成方法
|
|
EP3491026A4
(en)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND PROCESSES
|
|
MX2019001635A
(es)
|
2016-08-12 |
2019-06-10 |
Genentech Inc |
Terapia de combinacion con un inhibidor de mek, un inhibidor del eje de pd-1, y un inhibidor de vegf.
|
|
CN109862917A
(zh)
|
2016-09-29 |
2019-06-07 |
基因泰克公司 |
Mek抑制剂,pd-1轴抑制剂,和紫杉烷的组合疗法
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
JP2019535731A
(ja)
|
2016-11-21 |
2019-12-12 |
オービーアイ ファーマ，インコーポレイテッド |
コンジュゲートさせた生物学的分子、医薬組成物及び方法
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
SI3579883T1
(sl)
|
2017-02-08 |
2021-12-31 |
Adc Therapeutics Sa |
Konjugati pirolobenzodiazepin-protitelo
|
|
SMT202100543T1
(it)
|
2017-02-08 |
2021-11-12 |
Adc Therapeutics Sa |
Coniugati pirrolobenzodiazepina-anticorpo
|
|
CN106866624B
(zh)
*
|
2017-02-27 |
2017-12-26 |
济宁医学院 |
一种卡比替尼的化学合成方法
|
|
EP3606536A4
(en)
|
2017-04-04 |
2020-12-16 |
University of Miami |
INDICATIVE BIOMARKERS OF PROSTATE CANCER AND RELATED TREATMENT
|
|
SMT202200490T1
(it)
|
2017-04-18 |
2023-01-13 |
Medimmune Ltd |
Coniugati di pirrolobenzodiazepina
|
|
JP7402691B2
(ja)
|
2017-04-20 |
2023-12-21 |
アーデーセー セラピューティクス ソシエテ アノニム |
抗ｃｄ２５抗体薬物複合体による併用療法
|
|
US20200129637A1
(en)
|
2017-04-20 |
2020-04-30 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
|
WO2018229218A1
(en)
|
2017-06-14 |
2018-12-20 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-cd25 adc
|
|
EP3638373B1
(en)
|
2017-06-14 |
2024-09-04 |
ADC Therapeutics SA |
Dosage regimes for the administration of an anti-cd19 adc
|
|
CN111065638B
(zh)
|
2017-08-18 |
2021-04-09 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂䓬缀合物
|
|
WO2019051296A1
(en)
|
2017-09-08 |
2019-03-14 |
Genentech, Inc. |
DIAGNOSTIC AND THERAPEUTIC METHODS OF CANCER
|
|
WO2019158579A1
(en)
|
2018-02-13 |
2019-08-22 |
Vib Vzw |
Targeting minimal residual disease in cancer with rxr antagonists
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
US11833151B2
(en)
|
2018-03-19 |
2023-12-05 |
Taiho Pharmaceutical Co., Ltd. |
Pharmaceutical composition including sodium alkyl sulfate
|
|
WO2019183320A1
(en)
|
2018-03-21 |
2019-09-26 |
Colorado State University Research Foundation |
Cancer vaccine compositions and methods of use thereof
|
|
EP3757676A4
(en)
|
2018-03-26 |
2021-04-07 |
FUJIFILM Corporation |
LIGHT SENSITIVE RESIN COMPOSITION, METHOD OF MANUFACTURING THEREFORE, RESIST FILM, METHOD OF MANUFACTURING A PATTERN, AND METHOD OF MANUFACTURING ELECTRONIC DEVICE
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP3796942A1
(en)
|
2018-05-23 |
2021-03-31 |
ADC Therapeutics SA |
Molecular adjuvant
|
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
|
GB201811364D0
(en)
|
2018-07-11 |
2018-08-29 |
Adc Therapeutics Sa |
Combination therapy
|
|
JP2021531007A
(ja)
|
2018-07-20 |
2021-11-18 |
ピエール、ファーブル、メディカマン |
Ｖｉｓｔａに対する受容体
|
|
CA3107085A1
(en)
|
2018-08-31 |
2020-03-05 |
Adc Therapeutics Sa |
Combination of anti-cd19 antibody-pyrroloenzodiazepine conjugate and ve netoclax
|
|
US20210348238A1
(en)
|
2018-10-16 |
2021-11-11 |
Novartis Ag |
Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
|
|
US12378240B2
(en)
|
2018-11-20 |
2025-08-05 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
|
WO2020106305A1
(en)
*
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Thienyl-aniline compounds for treatment of dermal disorders
|
|
JP7406264B2
(ja)
*
|
2018-11-20 |
2023-12-27 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置のためのシアノアリール－アニリン化合物
|
|
CA3120351A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
|
WO2020109251A1
(en)
|
2018-11-29 |
2020-06-04 |
Adc Therapeutics Sa |
Dosage regime
|
|
GB201820725D0
(en)
|
2018-12-19 |
2019-01-30 |
Adc Therapeutics Sarl |
Pyrrolobenzodiazepine resistance
|
|
US20220347309A1
(en)
|
2018-12-19 |
2022-11-03 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine resistance
|
|
CA3124330A1
(en)
|
2018-12-21 |
2020-06-25 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
US12209099B2
(en)
|
2019-03-15 |
2025-01-28 |
Medimmune Limited |
Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
|
|
WO2020187674A1
(en)
|
2019-03-15 |
2020-09-24 |
Sandoz Ag |
Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
|
|
BR112021018168B1
(pt)
|
2019-03-21 |
2023-11-28 |
Onxeo |
Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
|
|
KR102498681B1
(ko)
|
2019-03-29 |
2023-02-09 |
메디뮨 리미티드 |
화합물 및 이의 접합체
|
|
TWI735210B
(zh)
|
2019-04-26 |
2021-08-01 |
中國醫藥大學 |
Ａｄａｍ９抑制劑作為免疫調節劑之用途
|
|
GB201908128D0
(en)
|
2019-06-07 |
2019-07-24 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
AU2020292965A1
(en)
|
2019-06-10 |
2022-01-27 |
Adc Therapeutics Sa |
Combination therapy comprising an anti-CD19 antibody drug conjugate and a PI3K inhibitor or a secondary agent
|
|
WO2020249527A1
(en)
|
2019-06-10 |
2020-12-17 |
Adc Therapeutics Sa |
Combination therapy comprising an anti-cd25 antibody drug conjugate and a further agent
|
|
GEP20247627B
(en)
|
2019-07-22 |
2024-05-27 |
Lupin Ltd |
Macrocyclic compounds as sting agonists and methods and uses thereof
|
|
GB201912059D0
(en)
|
2019-08-22 |
2019-10-09 |
Bergenbio As |
Combaination therapy of a patient subgroup
|
|
US20240123081A1
(en)
|
2019-10-25 |
2024-04-18 |
Medimmune, Llc |
Branched moiety for use in conjugates
|
|
US20220401436A1
(en)
|
2019-11-08 |
2022-12-22 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
|
GB201917254D0
(en)
|
2019-11-27 |
2020-01-08 |
Adc Therapeutics Sa |
Combination therapy
|
|
MX2022007164A
(es)
|
2019-12-13 |
2022-09-12 |
Inspirna Inc |
Sales metálicas y usos de estas.
|
|
CN111170990B
(zh)
*
|
2020-01-16 |
2021-01-05 |
广州科锐特生物科技有限公司 |
一种3-哌啶-2-基-氮杂环丁烷-3-醇衍生物的制备方法
|
|
TW202140076A
(zh)
|
2020-01-22 |
2021-11-01 |
英商梅迪繆思有限公司 |
化合物及其軛合物
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
CA3166732A1
(en)
|
2020-01-22 |
2021-07-29 |
Medimmune Limited |
Compounds and conjugates thereof
|
|
GB202004189D0
(en)
|
2020-03-23 |
2020-05-06 |
Bergenbio As |
Combination therapy
|
|
WO2021206167A1
(ja)
|
2020-04-10 |
2021-10-14 |
大鵬薬品工業株式会社 |
３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法
|
|
US11701427B2
(en)
|
2020-04-16 |
2023-07-18 |
Regeneron Pharmaceuticals, Inc. |
Diels-alder conjugation methods
|
|
GB202006072D0
(en)
|
2020-04-24 |
2020-06-10 |
Bergenbio Asa |
Method of selecting patients for treatment with cmbination therapy
|
|
EP3915576A1
(en)
|
2020-05-28 |
2021-12-01 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Chimeric antigen receptors specific for p95her2 and uses thereof
|
|
EP3939999A1
(en)
|
2020-07-14 |
2022-01-19 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
|
|
GB202011993D0
(en)
|
2020-07-31 |
2020-09-16 |
Adc Therapeutics Sa |
ANTI-IL 13Ra2 antibodies
|
|
GB202012161D0
(en)
|
2020-08-05 |
2020-09-16 |
Adc Therapeutics Sa |
Combination therapy
|
|
WO2022036171A1
(en)
|
2020-08-14 |
2022-02-17 |
Newave Pharmaceutical Inc. |
Dosage form compositions comprising an inhibitor of btk and mutants thereof
|
|
GB202015226D0
(en)
|
2020-09-25 |
2020-11-11 |
Adc Therapeutics S A |
Pyrrol obenzodiazepine-antibody conugates and uses thereof
|
|
GB202015916D0
(en)
|
2020-10-07 |
2020-11-18 |
Adc Therapeutics Sa |
Combination therapy
|
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
EP4304592A1
(en)
|
2021-03-09 |
2024-01-17 |
Genentech, Inc. |
Belvarafenib for use in treatment of brain cancers
|
|
EP4308935A1
(en)
|
2021-03-18 |
2024-01-24 |
Novartis AG |
Biomarkers for cancer and methods of use thereof
|
|
KR20230165795A
(ko)
|
2021-04-06 |
2023-12-05 |
제넨테크, 인크. |
벨바라페닙 및 코비메티닙 또는 벨바라페닙, 코비메티닙 및 아테졸리주맙을 이용한 병용 요법
|
|
US12280055B2
(en)
|
2021-05-27 |
2025-04-22 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
GB202107713D0
(en)
|
2021-05-28 |
2021-07-14 |
Medimmune Ltd |
Combination therapy
|
|
GB202107709D0
(en)
|
2021-05-28 |
2021-07-14 |
Adc Therapeutics S A |
Combination therapy
|
|
GB202107706D0
(en)
|
2021-05-28 |
2021-07-14 |
Adc Therapeutics S A |
Combination therapy
|
|
MX2023014565A
(es)
|
2021-06-09 |
2024-02-08 |
Chugai Pharmaceutical Co Ltd |
Tratamiento conjunto para tratamiento contra el cancer.
|
|
US20250352658A1
(en)
|
2021-06-29 |
2025-11-20 |
Adc Therapeutics Sa |
Combination therapy using antibody-drug conjugates
|
|
WO2023057545A1
(en)
|
2021-10-06 |
2023-04-13 |
Microquin Ltd. |
Substituted chalcones
|
|
EP4426305A1
(en)
|
2021-11-04 |
2024-09-11 |
F. Hoffmann-La Roche AG |
Novel use of quinazolinone compound for the treatment of cancer
|
|
CA3238962A1
(en)
|
2021-11-23 |
2023-06-01 |
Nflection Therapeutics, Inc. |
Formulations of pyrrolopyridine-aniline compounds
|
|
CA3238209A1
(en)
|
2021-12-16 |
2023-06-22 |
Christian Kuhne |
Cell penetrating polypeptides (cpps) and their use in human therapy
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
JP2025509657A
(ja)
*
|
2022-03-17 |
2025-04-11 |
スプリングワークス、セラピューティクス、インコーポレイテッド |
フッ素化フェニルアミノ化合物及び医薬組成物
|
|
EP4253418A1
(en)
|
2022-03-29 |
2023-10-04 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
|
|
GB202209285D0
(en)
|
2022-06-24 |
2022-08-10 |
Bergenbio Asa |
Dosage regimen for AXL inhibitor
|
|
WO2024033381A1
(en)
|
2022-08-10 |
2024-02-15 |
Vib Vzw |
Inhibition of tcf4/itf2 in the treatment of cancer
|
|
JP2025537786A
(ja)
|
2022-11-18 |
2025-11-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
進行性固形がんまたは転移の治療のためのｂｒａｆ阻害剤としてのキナゾリノン化合物
|
|
EP4406973A1
(en)
|
2023-01-27 |
2024-07-31 |
Fundació Privada Institut de Recerca de la SIDA-Caixa |
Antibodies and uses thereof for the treatment of infections caused by enveloped viruses
|
|
JPWO2024209717A1
(enExample)
|
2023-04-06 |
2024-10-10 |
|
|
|
WO2024229406A1
(en)
|
2023-05-04 |
2024-11-07 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
WO2025029650A1
(en)
|
2023-07-28 |
2025-02-06 |
Li Xiyan |
Nutritionally modified diets comprising aminoacids for use in treating a disease
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
WO2025080946A2
(en)
|
2023-10-12 |
2025-04-17 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|